Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

NCT03953456 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Continuation of the trial cannot serve a scientific purpose

Conditions

Non-Alcoholic Fatty Liver

Interventions

DRUG: elafibranor 120mg
DRUG: Placebo

Sponsor

Genfit